Guardant360 CDx Test Gets ADLT Status from CMS
The Guardant360 CDx test is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers.
Category: Cancer
Cancer
Latest
Cancer
Latest
Mayo Clinic Researchers Develop Test to Measure Effect of Breast Cancer Gene Variants
The lead researcher says the results will have a positive effect on patient care because patients will know whether breast cancer VUS are benign or pathogenic.
Cancer
Latest
Liquid Biopsy for Colorectal Cancer Could Guide Therapy for Tumors
The study suggests that such liquid biopsies could help personalize treatment for oligometastatic colorectal cancer.
Hologic, Google Cloud Collaborating on Digital Diagnostics for Cervical Cancer
The Hologic Genius Digital Diagnostics System is expected to derive even more actionable insights from cytology slides for cytotechnologists and pathologists with Google Cloud.
Read More
Spectrum Solutions, UCLA Collaborate on Saliva-Based NGS Liquid Biopsy Research for Early Detection of Lung Cancer
Study to focus on using saliva in the analysis of cell-free circulating tumor DNA to accurately and noninvasively detect non-small cell lung cancer.
Read More
Simple, Cheap Test Can Help Save Lives from Colorectal Cancer, Study Shows
New research has demonstrated that a simple, cheap test can help identify who is at risk of developing colorectal cancer, aiding early diagnosis and potentially saving lives.
Read More
Simplified Approach to Screening for Hereditary Cancers
MultiMMR, an alternative to complex, multistep testing workflows, was able to identify causes of MMR deficiency often missed by current clinical tests.
Read More
AI Algorithm Accurately Identifies 21 Cancer Types
Caris Life Sciences’ MI GPSai was validated on over 19,500 cases, predicting tumor types with an accuracy of over 94% on 93% of cases while deliberating among 21 possible categories of cancer.
Read More
Viewpoint | Support for the Pap Test
New survey results show strong support for this standby of cervical cancer screening.
Read More
HiberCell, Biodesix Partner on ELISA CDx for Cancer Immunotherapy
Through this agreement, Biodesix will develop a companion diagnostic to select patients for enrollment in HiberCell’s future registrational clinical trials.
Read More
Using Whole Transcriptome and Whole Exome Sequencing to Maximize Cancer Treatment
Growth of RNA sequencing allows physicians and researchers to analyze a patient’s full genetic profile.
Read More
InterVenn Achieves Milestones toward Development of Clinical Glycoproteomics Diagnostic
The company’s noninvasive liquid biopsy test for ovarian cancer will have final data from its initial clinical trial in the first half of 2021, and InterVenn’s on-site laboratory has received CLIA certification to make its tests available to the medical community.
Read More
Myriad Genetics, Illumina Form Strategic Partnership in Oncology
The strategic partnership between Myriad and Illumina consists of a time-limited exclusive agreement for Illumina to provide a kit-based version of the myChoice CDx test for international markets.
Read More
Illumina Partners with 4 Companies to Advance Genomic Profiling for Oncology
Illumina has established oncology partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to expand the reach of TruSight Oncology.
Read More
Roche Launches 2 Digital Pathology Image Analysis Algorithms for Precision Breast Cancer Diagnosis
uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer use AI to aid pathologists’ decision-making.
Read More
LabPON Adopts Proscia’s Concentriq to Meet Demand for Cancer Diagnostic Services
With Concentriq, LabPON gains added flexibility to scale its routine digital pathology operations as the total number of worldwide cancer cases continues to rise.
Read More
Hologic to Acquire Molecular Diagnostics Company Biotheranostics
Biotheranostics is a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers.
Read More
Oncotype DX Test Can Spare Chemotherapy for Women with Certain Breast Cancers
Data from RxPONDER trial successfully defined the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Oncotype DX Breast Recurrence Score results of 0 to 25.
Read More
- 1
- ...
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- ...
- 120